Genflow Biosciences PLC Appointment of Joint Broker (7060S)
08 Novembre 2023 - 8:00AM
UK Regulatory
TIDMGENF
RNS Number : 7060S
Genflow Biosciences PLC
08 November 2023
8 November 2023
Genflow Biosciences Plc
("Genflow" or "the Company")
Appointment of Joint Broker
The Company (LSE:GNF) (OTCQB:GENFF) , is pleased to announces
today that it has appointed Capital Plus Partners Ltd to act as
Joint Broker, alongside Clear Capital Markets, with immediate
effect.
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
For further information please contact:
Genflow Biosciences Plc
Dr Eric Leire
Chief Executive Officer +32 477 495 881
-------------------
Clear Capital Markets
-------------------
Joint Corporate Broker
Bob Roberts +44 203 869 6080
-------------------
Capital Plus Partners Ltd
-------------------
Joint Corporate Broker
Dominic Berger +44 203 821 6167
About Genflow Biosciences
Genflow is a UK-based biotechnology company established in 2020.
The Company is developing gene therapies designed to target the
aging process and to reduce and delay the incidence of age-related
diseases. This will be done through novel therapeutics targeting
aging in humans by using adeno-associated virus ("AAV") vectors to
deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is
found in centenarians into cells.
Its mission is to increase our understanding of the factors that
control and impact lifespan. Genflow researches, develops, and
commercialises therapeutic solutions to lengthen health span, the
amount of time we live in good health, creating biological
interventions that enable longer and healthier lives. Genflow is
dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging,
Genflow can contribute to a decrease in healthcare costs and lessen
the emotional and societal burden that comes with an aging
population.
To learn more visit www.genflowbio.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPKZMGMRNRGFZM
(END) Dow Jones Newswires
November 08, 2023 02:00 ET (07:00 GMT)
Grafico Azioni Genflow Biosciences (LSE:GENF)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Genflow Biosciences (LSE:GENF)
Storico
Da Set 2023 a Set 2024